These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36304988)

  • 1. Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2.
    Duan A; Li H; Yu W; Zhang Y; Yin L
    J Oncol; 2022; 2022():4537343. PubMed ID: 36304988
    [No Abstract]   [Full Text] [Related]  

  • 2. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
    Wang Y; Tan K; Hu W; Hou Y; Yang G
    Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the lncRNA HOTAIRM1 promotes lenvatinib resistance by downregulating miR-34a and activating autophagy in hepatocellular carcinoma.
    Gu D; Tong M; Wang J; Zhang B; Liu J; Song G; Zhu B
    Discov Oncol; 2023 May; 14(1):66. PubMed ID: 37171645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.
    Huang M; Long J; Yao Z; Zhao Y; Zhao Y; Liao J; Lei K; Xiao H; Dai Z; Peng S; Lin S; Xu L; Kuang M
    Cancer Res; 2023 Jan; 83(1):89-102. PubMed ID: 36102722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
    He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
    Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
    Tao M; Han J; Shi J; Liao H; Wen K; Wang W; Mui S; Li H; Yan Y; Xiao Z
    J Hepatocell Carcinoma; 2023; 10():1069-1083. PubMed ID: 37457652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met.
    Xu X; Jiang W; Han P; Zhang J; Tong L; Sun X
    J Hepatocell Carcinoma; 2022; 9():113-126. PubMed ID: 35252056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib.
    Yang CJ; Wu MH; Tsai JJ; Hsu FT; Hsia TC; Liu KC; Kuo YC
    Anticancer Res; 2022 May; 42(5):2495-2505. PubMed ID: 35489726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma.
    Sun D; Liu J; Wang Y; Dong J
    Front Oncol; 2022; 12():944537. PubMed ID: 36158676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Underlying Mechanisms of Noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma.
    Wang M; Yu F; Chen X; Li P; Wang K
    Mol Ther Nucleic Acids; 2020 Sep; 21():13-27. PubMed ID: 32505000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin.
    Guo Y; Xu J; Du Q; Yan Y; Geller DA
    Transl Oncol; 2021 Jun; 14(6):101059. PubMed ID: 33735820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
    Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
    Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
    [No Abstract]   [Full Text] [Related]  

  • 14. CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.
    Hao X; Zhang Y; Shi X; Liu H; Zheng Z; Han G; Rong D; Zhang C; Tang W; Wang X
    J Exp Clin Cancer Res; 2022 Sep; 41(1):281. PubMed ID: 36131287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
    Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
    Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance.
    Lu Y; Shen H; Huang W; He S; Chen J; Zhang D; Shen Y; Sun Y
    Cell Death Discov; 2021 Nov; 7(1):359. PubMed ID: 34795217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214.
    Huang X; Gao Y; Qin J; Lu S
    Am J Physiol Gastrointest Liver Physiol; 2018 May; 314(5):G559-G565. PubMed ID: 29097358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
    Li Y; Ye Y; Feng B; Qi Y
    J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.